AMRI files two new patent infringement lawsuits

AMRI (NASDAQ: AMRI) announced today that it has filed two new patent infringement lawsuits in U.S. District Court in New Jersey against Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc. and Sandoz, Inc. (“the defendants”) for infringement of AMRI’s U.S. Patent Number 7,390,906. The recently issued patent relates to the manufacturing process for the active ingredient in sanofi-aventis’s Allegra® and Allegra®D drug products.

This legal action relates to generic versions of sanofi-aventis’s Allegra® and Allegra®D drug products for which the defendants are seeking or have obtained marketing approval from the U.S. Food and Drug Administration (“FDA”) and which the defendants have marketed in the United States.

“We believe that this patent infringement filing strengthens our litigation strategy on Allegra®, Allegra®D-12, and Allegra®D-24 against these generic drug companies in the United States and other jurisdictions. AMRI remains committed to vigorously protecting and enforcing its intellectual property,” said AMRI Chairman, President and CEO Thomas E. D'Ambra.

In November 2008, AMRI announced a settlement regarding two U.S. patent infringement litigations involving Allegra® and Allegra®D-12 to allow sanofi-aventis U.S. LLC to sublicense patents related to Allegra® and Allegra®D-12 to Teva Pharmaceuticals, USA, Inc. and Barr Laboratories, Inc. in the United States for which AMRI receives royalties on the sale of products containing fexofenadine hydrochloride (the generic name for the active ingredient in Allegra® ) and products containing fexofenadine hydrochloride and pseudoephedrine hydrochloride (generic Allegra®D-12) by Teva Pharmaceuticals, USA, Inc. and Barr Laboratories, Inc. through 2015, along with additional considerations.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MD Anderson launches new institute for advancing cell therapy